Uno N, Minami N, Tanaka I, Katayama N, Kamio N, Kataoka Y, Ota C, Koh T, Ono T, Kageyama S
Jpn J Antibiot. 1984 May;37(5):807-16.
Clinical investigation of combination use of cefotiam (CTM), aminoglycoside, or (and) penicillin against complicated infections with hematopoietic disorders was performed, and the results were as follows. Fifty-one patients were administered CTM in combination with aminoglycoside or (and) penicillin. The clinical response was excellent 19.6%, good 27.4%, fair 21.6%, and poor 31.4% showing efficacy rate of 47.1%. The combined therapy of CTM and aminoglycoside was clinical effective in 70% of 10 patients with complicated sepsis. Therefore, combination use of CTM and aminoglycoside is considered to be the first choice for the treatment of complicated sepsis with hematopoietic disorders. The clinical effectiveness of CTM was not influenced by the number of mature neutrophil at the first phase of CTM treatment, but was influenced at the end phase of CTM treatment. Gram-negative bacilli were dominantly isolated from the patients. Pseudomonas sp. was isolated from 70% of the patients with sepsis. No remarkable side effects were observed in this investigation.
进行了头孢替安（CTM）联合氨基糖苷类药物或（和）青霉素治疗造血系统疾病合并感染的临床研究，结果如下。51例患者接受了CTM联合氨基糖苷类药物或（和）青霉素治疗。临床反应为：优19.6%，良27.4%，中21.6%，差31.4%，有效率为47.1%。CTM与氨基糖苷类药物联合治疗10例复杂性败血症患者，70%临床有效。因此，CTM与氨基糖苷类药物联合使用被认为是治疗造血系统疾病合并复杂性败血症的首选。CTM治疗初期成熟中性粒细胞数量不影响其临床疗效，但在治疗末期会产生影响。革兰氏阴性杆菌是从患者中分离出的主要病菌。70%的败血症患者分离出假单胞菌属。本研究未观察到明显副作用。
